Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Assay Kit / ADA/PK Assay Elisa Kit

Lorvotuzumab ELISA Kit

Catalog #:   KDC98501 Specific References (27) DATASHEET
Applications: Used for the quantitative determination of Lorvotuzumab concentration in serum and plasma.
Sample type: Plasma, Serum
Sensitivity: 32.98 ng/mL
Range: 31.25 - 2,000 ng/mL
Overview

Catalog No.

KDC98501

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD56 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Lorvotuzumab in the sample competitively binds to the pre-coated protein with biotin-labeled Lorvotuzumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Lorvotuzumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Lorvotuzumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

31.25 - 2,000 ng/mL

Sensitivity

32.98 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

 

Intra-Assay Precision

Inter-Assay Precision

Sample

1

2

3

1

2

3

n

16

16

16

24

24

24

Mean (ng/mL)

571.0

112.9

40.2

592.8

123.0

35.3

Standard deviation

39.5

13.9

8.0

54.2

18.5

7.0

CV (%)

6.9

12.3

20.0

9.1

15.0

19.9

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

BB-10901, IMGN901, huN901-DM1, CAS: 1008106-64-6

Background

Lorvotuzumab mertansine (IMGN901, BB10901, huN901-DM1) is an antibody-drug conjugate (ADC) composed of the cytotoxic maytansinoid derivative, DM1, conjugated to the humanized N901 monoclonal antibody (lorvotuzumab, huN901), which binds CD56 with high affinity. DM1 conjugated to lorvotuzumab via a stable disulfide SPP linker (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine). It was developed by ImmunoGen, Inc. Lorvotuzumab mertansine is designed for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer). It has been granted orphan drug status for Merkel cell carcinoma and has reported encouraging Phase II results for small-cell lung cancer (SCLC). Once bound to CD56 on the surface of the target cell, the conjugate is internalized, the linker is cleaved, DM1 is released which in turn inhibits tubulin polymerization and results in cell death. Maytansine is a natural product, originally derived from the Ethiopian shrub Maytenus serrata. Maytansine inhibits tubulin polymerization, and is approximately 200-1,000 fold more cytotoxic than the Vinca alkaloids. Maytansine is clinically active but its narrow therapeutic window precluded further clinical development. Conjugation to an antibody and intracellular delivery could take advantage of the cytotoxic potency and expand the therapeutic window leading to greater tumor cell death with less overall toxicity. The maytansine derivative DM1 was developed specifically for use in ADCs.

Data Image
  • Experiment Example
    CALCULATION OF RESULTS
    Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. Do not include the blank in the standard curve. The data may be linearized by plotting the log of the Lorvotuzumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
References

Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics., PMID:37430453

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer., PMID:34942494

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study., PMID:32914879

Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development., PMID:31544840

NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target., PMID:31477684

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma., PMID:30340993

Advances in antibody therapeutics targeting small-cell lung cancer., PMID:29790694

Emerging immune targets for the treatment of multiple myeloma., PMID:29421983

Emerging antibody-drug conjugates for treating lymphoid malignancies., PMID:28792782

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease., PMID:28341109

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML., PMID:28321813

Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis., PMID:27935326

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors., PMID:26961907

Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates., PMID:26927803

Monoclonal antibodies in myeloma., PMID:26452191

Monoclonal antibodies - A new era in the treatment of multiple myeloma., PMID:26362528

Novel formulations and new mechanisms of delivering chemotherapy., PMID:24857128

Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies., PMID:24708159

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models., PMID:24492307

Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma., PMID:24389179

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program., PMID:23798344

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients., PMID:23721099

The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets., PMID:23239665

Drug-conjugated antibodies for the treatment of cancer., PMID:23173552

Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany., PMID:22909934

ADME of antibody-maytansinoid conjugates., PMID:22875610

Immunoconjugates against solid tumors: mind the gap., PMID:21368753

Datasheet

Document Download

Lorvotuzumab ELISA Kit.pdf

 

$ 1128
Product specifications
96 T 1128

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Lorvotuzumab ELISA Kit [KDC98501]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only